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To improve our understanding of the biological relationships among different types of cancer, we have
characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer
types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). In the unified
dataset, breast tumors of the Basal-like subtype were found to represent a unique molecular entity as any
other cancer type, including the rest of breast tumors, while showing striking similarities with squamous cell
lung cancers. Moreover, gene signatures tracking various cancer- and stromal-related biological processes
such as proliferation, hypoxia and immune activation were found expressed similarly in different
proportions of tumors across the various cancer types. These data suggest that clinical trials focusing on
tumors with common profiles and/or biomarker expression rather than their tissue of origin are warranted
with a special focus on Basal-like breast cancer and squamous cell lung carcinoma.
C
lassification and treatment of themajority of solid tumors is generally based on the tumor’s tissue of origin
and histological appearance (e.g. squamous cell lung cancer). In some cancer types, identification of single
molecular alterations has been found to be very useful in the clinical setting due to its ability to predict
treatment efficacy. For example, epidermal growth factor receptor (EGFR) mutations predict benefit from anti-
EGFR drugs in lung adenocarcinoma1, amplification of epidermal growth factor receptor type 2 (HER2) predicts
benefit from anti-HER2 drugs in breast cancer2, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations
predict lack of benefit from anti-EGFR drugs in colorectal cancer3 and BRCA1 mutations predict benefit from
poly (ADP-ribose) polymerase 1 (PARP1) inhibitors in ovarian cancer4. Thus, searching for novel biomarkers,
drug targets and better classification algorithms to individualize treatment of cancer patients is an area of active
preclinical and clinical research.
In recent years, The Cancer Genome Atlas (TCGA) project has improved our understanding of the molecular
alterations occurring in glioblastomamultiforme5,6, high grade serous ovarian cancer7, colorectal cancer8, squam-
ous cell lung cancer9 and breast cancer10 and many other cancer types are being evaluated. In addition, these
studies have revealed that particular molecular alterations such as TP53 mutations, MYC amplifications or
CDKN2A deletions can occur in subsets of tumors of different cancer types. In fact, TCGA breast cancer project
has observed that breast tumors of the Basal-like subtype share many genetic alterations with high-grade serous
ovarian cancers, including TP53, RB1 and BRCA1 loss, CCNE1 andMYC amplifications, and high expression of
HIF1-a/ARNT, MYC and FOXM1 gene signatures10,11. Overall, these data suggest that particular treatment
strategies could be effective in tumors with similar genetic alterations and/or gene expression profiles regardless
of the tumor’s tissue of origin11,12. Indeed, the observed benefit of anti-HER2 therapy in HER2-amplified breast
and gastric cancers supports this hypothesis13,14.
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To help better understand the relationships among different types
of cancer, we have compared head-to-head variation in global gene
expression patterns in a dataset of 1,707 samples representing 6
human cancer types.
Results
Combined microarray dataset. To study the relationships among
different cancer types, we combined expression data of 17,987 genes
and 1,707 samples representing 6 cancer types (glioblastoma multi-
forme [GBM]5,6, high-grade serous ovarian carcinoma [OVARIAN]7,
lung cancer adenocarcinoma [LUAD], squamous cell lung carcinoma
[SQCLC]9, colorectal adenocarcinoma [CCR]8 and breast cancer10) of
the TCGA project (Fig. 1A). The cancer type with the highest gene
expression variability was ovarian cancer with 9.1% of the genes
showing an interquartile range of expression above 3-fold, followed
closely by breast cancer (8.9%), LUAD (8.8%) and SQCLC (8.3%).
CCR (4.6%) and GBM (4.5%) showed the lowest gene expression
variability, suggesting that these two cancer types are biologically
more homogenous.
Global gene expression landscape. To assess the global landscape of
expression in the unified dataset, we performed principal compo-
nents analysis (PCA)15. Brain, colorectal and breast cancer explained
most of the gene expression variation displayed by the Principal
Components 1 and 2 (PC1 and PC2) with samples of ovarian
cancer, LUAD and SQCLC showing various levels of intermediate
PC1 and PC2 scores (Fig. 1B). Strikingly, a subgroup of breast
cancers almost entirely composed of the Basal-like subtype (in red
color), as determined by the PAM50 subtype predictor, showed
significant higher PC2 scores than the rest of breast tumors (i.e.
Luminal/HER2-enriched/Normal-like) and were found close to
ovarian cancers, SQCLCs and LUADs (Fig. 1B). Similar PC1
versus PC2 results were obtained from an independent gene
expression-based microarray dataset of 153 samples representing
breast cancer, LUAD, SQCLC and CRC (Suppl. Fig. 1).
To better understand the biological significance of PC1 and PC2,
we evaluated the top-300 genes having the largest positive and nega-
tive weights for both PCs (Fig. 1C and Supplemental Data). Gene
weights are indicative of the relative contribution of each gene to the
principal components. For PC1, the top-300 genes having the largest
positive weight were found enriched for neuron differentiation (e.g.
neuronal cell adhesion molecule [NRCAM] and N-cadherin
[CDH2]), gliogenesis (e.g. SRY [sex determining region Y]-box 11
[SOX11]), cell-cell signaling (e.g. synaptotagmin IV [SYT4]) and
synaptogenesis (e.g. neurexin 1 [NRXN1]), whereas the top-300
genes having the largest negative weight were found enriched for
tight junctions (e.g. claudin-3 [CLDN3]), epithelial cell differenti-
ation (i.e. FOXA1) and extracellular matrix (e.g. collagen, type XII,
Figure 1 | Combined gene expressionmicroarray-based dataset of 1,707 samples representing 6 different cancer types fromThe Cancer Genome Atlas
Project (TCGA; http://cancergenome.nih.gov/). (A) Microarray samples analyzed from each cancer type (number of samples and color identification).
(B) Principal component 1 and 2 (PC1 and PC2) loading plot using the 3,486 most variable genes. Samples have been colored based on their cancer type,
except for Basal-like breast tumors (n 5 98) that are colored in red. Weights of each gene for each PC can be found in Supplemental Data. (C)
Correlations between PC1 or PC2 scores and expression of selected genes in the entire dataset. (D) Consensus average linkage clustering matrix for k5 3
to k5 6 of all samples and the 3,486most variables genes. The colored bar above thematrix identifies the various cancer types represented in each k group.
A single cancer type is shown in the bar if.98% of the samples of each k group are from that particular cancer type. Orange, GBM;Dark blue, OVARIAN;
Light blue, CCR; Grey, SQCLC; Green, BREAST; Violet, LUAD; Red, Basal-like breast cancer.
www.nature.com/scientificreports
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alpha 1 [COL12A1]). For PC2, the top-300 genes having the largest
positive weight were found enriched for serine proteases (e.g. kallik-
rein-related peptidase 7 [KLK7]), drug metabolism (i.e. CYP3A7)
and chemokines (e.g. interleukin-8 [IL8]), whereas the top-300 genes
having the largest negative weight were found enriched for response
to hormone stimulus (e.g. estrogen receptor [ESR1] and GATA3),
cell adhesion (e.g. claudin-8 [CLDN8]) and extracellular matrix (e.g.
fibronectin 1 [FN1]). Similar biological findings were obtained when
the top-100, top-200 and top-400 genes were evaluated (data not
shown).
Testing the molecular uniqueness of Basal-like breast cancer. The
previous results suggested that Basal-like breast cancer ismolecularly
distinct from the other cancer types, including the rest of breast
tumors. To test the level of uniqueness of Basal-like breast tumors,
we performed consensus average linkage hierarchical clustering of all
samples (n5 1,707) and the 3,486most variable genes (Fig. 1D). The
consensus clustering method provides quantitative and visual
stability evidence for estimating the number of unsupervised
classes in a dataset16. The results showed that clustering stability
increased for k 5 2 to k 5 7 (Suppl. Fig. 2). Strikingly, Basal-like
breast cancer was identified as an unsupervised class at k5 5 before
colorectal cancer was separated from both lung cancer types (i.e. at k
5 6) and before both lung cancer types were separated from each
other (i.e. at k5 7). Overall, this result suggests that Basal-like breast
cancer is a reproducible and robust cancer type.
Expression of gene signatures corresponding to human DNA
regions. Somatic copy number aberrations (CNAs) in breast cancer
are associated with expression in ,40% of genes17. To estimate the
status of CNAs in our combined dataset, we evaluated the expression
of 326 gene sets corresponding to each human chromosome and each
cytogenetic band with at least one gene. These gene lists were
obtained from the C1-positional gene sets of the Molecular
Signature Database (Broad Institute; http://www.broadinstitute.org/
gsea/msigdb/), and are helpful in identifying effects related to
chromosomal deletions or amplifications.
Unsupervised hierarchical clustering of the 326 signature scores
and the 1,707 samples revealed significant changes in the expression
of genes located in specific DNA regions known to be aberrant in
these cancer types (Fig. 2A–B). For example, high expression of arm
1q-related genes in breast cancer (including Basal-like tumors)10, or
high expression of arm13q-related genes inCCRs8, or low expression
of arm 10q-related genes in GBMs5,6. In addition, we identified high
expression of arm 10p-related genes and low expression of arm 5q-
related genes in Basal-like breast tumors concordant with the known
CNA status of these two chromosomal regions in Basal-like disease10.
Finally, Basal-like breast cancers, SQCLCs and OVARIAN carcino-
mas clustered together consistent with the hypothesis that these three
cancer types share a similar genetic profile with a special focus on
3q21-28 (amplified) and 5q13-22 (deleted) chromosomal regions
(Fig. 2B).
Gene expression relationships among cancer types. To address the
relationships among the 7 cancer types (i.e. Basal-like breast cancer
[identified by the PAM50 subtype predictor], non-Basal-like breast
cancer, CCR, GBM, SQCLC, LUAD and OVARIAN), we first
identified gene expression-based centroids, representing the 7
groups, using all available genes (n 5 17,987). Second, we evalu-
ated the relationships among the different centroids within all
samples (Fig. 3A), Basal-like breast tumors (Fig. 3B), OVARIAN
tumors (Fig. 3C), SQCLCs (Fig. 3D), LUADs (Fig. 3E), CCRs
(Fig. 3F), GBMs (Fig. 3G) and non-Basal-like breast tumors
(Fig. 3H).
Strikingly, the Basal-like breast tumor centroid was found more
similar to the SQCLC centroid than to the centroid of non-Basal-like
Figure 2 | Expression of 326 gene signatures corresponding to human DNA regions across 7 cancer types. Signatures have been obtained from the
Molecular Signatures Database (MSigDB) from the Broad Institute online website (http://www.broadinstitute.org/gsea/msigdb/collections.jsp; C1:
positional gene sets). (A)Unsupervised clustering of 326 signatures scores across 1,707 samples. Each colored square on the heatmap represents the relative
median signature score for each sample with highest expression being red, lowest expression being green and average expression being black. Below the
array tree, samples have been colored based on their cancer type. (B) The top-10 up-regulated and down-regulated significant signatures for each cancer
type (or group) are shown. These signatures were identified by performing an unpaired two-class SAM analysis between each cancer type versus the rest
using the 326 signatures and a FDR 5 0%.
www.nature.com/scientificreports
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breast cancer (Fig. 3B). Concordant with this, 55% of Basal-like
breast tumors were found more similar (i.e. lower distances) to
SQCLCs than to non-Basal-like breast cancers. When compared to
the different intrinsic subtypes of breast cancer, 76%, 72% and 17%of
Basal-like breast tumors were found more similar to SQCLC than to
Luminal A, Luminal B and HER2-enriched breast tumors, respect-
ively. Interestingly, Basal-like breast tumors were foundmore similar
to both lung cancer types and to non-Basal-like breast cancers than to
OVARIAN tumors (Fig. 3B).
To determine the biological processes in common between Basal-
like breast cancers and SQCLC, we identified genes whose expression
is found significantly expressed in both cancer types compared to
luminal cancers (Luminal A and B tumors combined). Among the
top 300 up-regulated genes (False Discover Rate5 0%) in Basal-like
breast cancer and SQCLC, we identified genes involved in ectoder-
mal differentiation (e.g. keratin 5, 14 and 17), inflammatory response
(i.e. chemokine [C-X-C motif] ligand 1 [CXCL1] and CXCL3) and
cell cycle (e.g. cyclin E1 [CCNE1] and centromere protein A
[CENPA]). Among the top 300 down-regulated genes, we identified
genes involved in the response to hormone stimulus (e.g. estrogen
receptor [ESR1] and GATA3), mammary gland development (e.g.
prolactin receptor [PRLR] and ERBB4) and microtubule-based pro-
cess (e.g. kinesin family member 12 [KIF12] and microtubule-assoc-
iated protein tau [MAPT]). This data is concordant with the
histological appearance and the immunohistochemical expression
of ER, keratins 5/6 and the proliferation-related biomarker Ki67 in
a Basal-like breast tumor, a SQCLC with a Basal-like profile and a
breast Luminal A tumor (Fig. 4).
Multiclass tumor prediction. To identify genes that are distinctive of
each cancer type, including Basal-like breast cancer, we performed
ClaNC, a nearest centroid-based classifier that balances the number
of genes per class (Fig. 5A). A 126-gene signature (18 genes per cancer
type) was established from the smallest gene set with the lowest cross
validation and prediction error (2.0%) (Fig. 5B). Among the various
cancer types, Basal-like breast cancers and SQCLCs showed the
highest prediction error (7.1% and 15.6%), and the majority of
misclassified SQCLCs (n 5 5, 71.4%) were identified as Basal-like
breast cancer. Of note, two previously identified diagnostic biomar-
kers of serous ovarian cancer (Wilm’s tumor [WT]-1)18 and lung
adenocarcinoma (thyroid nuclear factor 1 [TITF-1])19 were found
in the 18-gene list of these two cancer types (Fig. 5C).
Common patterns of gene expression across cancer types.Although
each cancer type is molecularly distinct, we sought to identify groups
of genes (i.e. gene signatures) with independent patterns of variation.
To accomplish this, we clustered all samples with the 3,486 most
variable genes (Fig. 6) and identified 19 gene clusters of at least 10
genes and an intraclass correlation coefficient .0.70 (Supplemental
Data). Among them, we identified gene signatures tracking lympho-
cyte activation/infiltration (e.g. CD8A and CD2), ectodermal
development (e.g. keratin 6B and 15), interleukin-8 pathway (e.g.
IL8 and CXCL1), tight junctions (e.g. claudin-3 and occludin),
proliferation (e.g. budding uninhibited by benzimidazoles 1 homo-
log [BUB1] and CENPA) and interferon-response pathways (e.g.
STAT1 and interferon-induced protein with tetratricopeptide repeats
1 [IFIT1]) (Fig. 6).
Common patterns of gene signature expression across cancer
types. Similar to the previous analysis, we determined the expres-
sion scores of 329 gene signatures (or modules)20 in all samples,
including 115 previously published signatures, and then performed
an unsupervised hierarchical clustering (Fig. 7). Thirteen clusters of
at least 5 signatures and an intraclass correlation coefficient .0.70
were identified. These groups of gene signatures were found to track
various types of biological processes/features likely coming from the
tumor cell, the microenvironment or both. Interestingly, the expres-
sion of signatures tracking microenvironment-related (e.g. lympho-
cyte activation/infiltration) biological processes were found to be less
cancer type specific than the expression of gene signatures tracking
tumor-related biological processes (e.g. proliferation).
To illustrate the overlap among cancer types regarding the
expression of a single signature, we evaluated 6 previously identified
gene signatures that are known to track various cancer-related and
stromal/microenviroment-related biological processes related to
breast cancer biology21,47–51. The results showed that high expression
of these signatures (i.e. the top 20% expressers in the unified dataset)
occurs across all cancer types, albeit with different proportions
(Fig. 8). Of note, the TP53 signature21, which was trained in a prev-
iously reported breast cancer dataset, predicted TP53 somatic muta-
tions in the combined TCGA dataset (area under the receiver
operating characteristic curve 5 0.782; Suppl. Fig. 3). Moreover,
the scores of the previously reported PTEN-loss signature were
found correlated with INPP4B (correlation coefficient 5 20.424,
p-value , 0.0001) and phospho-4E-BP1 (correlation coefficient 5
0.368, p-value , 0.0001) protein expression in the TCGA breast
cancer dataset (Suppl. Fig. 4).
Breast cancer intrinsic subtyping of non-breast tumors. To evalu-
ate if the breast cancer ‘intrinsic’ profiles (Luminal A, Luminal B,
Figure 3 | Transcriptomic relationships among cancer types. Relationships have been determined by calculating the Euclidean distances of each sample
to each of the 7 centroids, which represent each cancer type, using all genes of the unified dataset. Clustering has been performed after median
centering the Euclidean distances of each sample. The following genomic relationships among cancer types are shown based on the following subsets of
patients: (A) all patients (ALL); (B) basal-like breast cancer (BASAL-LIKE); (C) ovarian cancer (OVARIAN); (D) squamous cell lung cancer (SQCLC);
(E) lung adenocarcinoma (LUAD); (F) colorectal adenocarcinoma (CCR); (G) glioblastoma multiforme (GBM); (H) non-Basal-like breast cancer
(BREAST).
www.nature.com/scientificreports
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HER2-enriched and Basal-like) can be identified in non-breast
tumors, we performed breast cancer intrinsic subtyping of non-
breast cancer types using the PAM50 and Claudin-low subtype
predictors22,23. Interestingly, all the breast cancer ‘intrinsic’ profiles
were identified albeit with different proportions (Table 1). For
example, the Basal-like profile was identified in 55% and 53% of
SQCLC and ovarian cancers, respectively, whereas virtually all
colorectal cancers (99%), and most lung adenocarcinomas (59%)
showed the HER2-enriched profile. Of note, 28% of ovarian
cancers and 24% of SQCLC tumors also showed the HER2-
enriched profile. Finally, the Claudin-low profile was identified in
20% and 16% of SQCLCs and LUADs, respectively.
To provide further evidence, we performed breast cancer intrinsic
subtyping of non-breast cancer types in two independent datasets
(Suppl. Fig. 5 and 6). First, we evaluated a publicly available micro-
array dataset (GSE23768) that includes 153 samples of breast cancer
Figure 4 | Immunohistochemical (IHC) and PAM50 gene expression analyses of a Basal-like breast cancer, a SQCLC with a Basal-like profile and a
Luminal A breast cancer. Hematoxylin/eosine (H/E); Estrogen receptor (ER) expression; Keratin 5/6 (KRT5/6) expression; Proliferation-related Ki-67
expression. Each colored square on the heatmap below the IHC images represents the relative transcript abundance (in log2 space) of each PAM50
gene with highest expression being red, lowest expression being green and average expression being black.
www.nature.com/scientificreports
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(n 5 84), CCR (n 5 26), SQCLC (n 5 22) and LUAD (n 5 21)24
(Suppl. Fig. 5). Similar to previous results, 92.3% and 7.7% of all
CCRs were identified as HER2-enriched and Basal-like, and 59.1%
and 27.3% of SQCLCs were identified as Basal-like and Claudin-low,
respectively.
Finally, we evaluated PAM50 gene expression in a dataset from
Vall d’Hebron Institute of Oncology that includes 125 formalin-fixed
paraffin-embedded tumor samples of breast cancer (n 5 53) and
CCR (n 5 72) (Suppl. Fig. 6). Similar to previous results, 88.9%
and 11.1% of all CCRs were identified as HER2-enriched and
Basal-like, respectively. Of note, ERBB2was not found overexpressed
in these CRCs HER2-enriched tumors, except for 1 case (1.4%),
which we found highly amplified in HER2 by FISH (ratio gene/chro-
mosome 5 7.23) (Suppl. Fig. 7).
Discussion
In this study, we have evaluated global gene expression data of 6
human cancer types from the TCGA project, and made the following
observations. First, a group of breast cancers, virtually all of the Basal-
like subtype, have a unique and distinct profile as the profile of any of
the other cancer types, including the rest of breast tumors. Second,
although Basal-like breast tumors and high grade serous ovarian car-
cinomas may share similar genetic alterations10, our transcriptomic
analyses show that the majority of Basal-like tumors are more similar
to SQCLCs than to high grade serous ovarian carcinomas and the rest
of breast tumors. Indeed, when compared with each breast cancer
intrinsic subtype, ,70% Basal-like tumors were found more similar
to SQCLC than Luminal A and B breast tumors. Third, we identified
cancer type specific genes and confirmed the association of WT-1 and
TITF-1 expression with the identification of serous ovarian cancer and
LUAD, respectively. Finally, we provided evidence that distinct gene
signatures can be found expressed regardless of the cancer type. For
example, we identified the Basal-like breast cancer profile in the
majority of SQCLC and ovarian cancers, whereas the HER2-enriched
breast cancer profile was found expressed in a subset of ovarian can-
cers and SQCLCs and the majority of LUADs and CCRs.
The observation that Basal-like breast cancer is remarkably different
from the rest of breast tumors argues for two distinct cells of origin in
the mammary gland25. In fact, ducts and lobules in the normal human
breast are lined by two cell layers, an inner/luminal cell population
Figure 5 | Identification of a cancer type-specific 126-gene signature. (A) Clustering of the 126-gene scores obtained after Classification by Nearest
Centroids (ClaNC) analysis. Discriminative genes are shown in red and in green color. (B) Training error of the 126-gene signature across the 7 cancer-
types. (C) Genes whose high (red) or low (green) expression define each cancer type. Gene Symbols are shown first, followed by the Entrez GeneIDs.
www.nature.com/scientificreports
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that expresses luminal keratins such as keratins 8, 18 and 19 as well as
BCL2, MUC1 and estrogen receptor, and a distinct outer cell layer,
named the basal layer, which is composed of cells that exhibit features
of both epithelial and smooth muscle cells such as expression of
keratins 5, 14 and 17, smooth muscle actin and p63. However, basal
keratins are also expressed in a subpopulation of luminal cells26,27 and
preclinical mouse work has shown conflicting data regarding the cell
of origin of Basal-like breast tumors28–31 (i.e. luminal progenitor versus
Figure 6 | Unsupervised hierarchical clustering of 7 different cancer types and the 3,486 most variable genes. (A) Tumor samples have been ordered
based on the consensus clustering matrix (Fig. 1D). Each colored square on the heatmap represents the relative median transcript abundance (in log2
space) for each sample with highest expression being red, lowest expression being green and average expression being black. (B) Expression of selected
gene clusters tracking several cancer-related biological processes. Clusters were selected based on the following criteria: at least 10 genes and an
intraclass correlation coefficient .0.70. Colored bars to the right identify the locations of the selected clusters. The gene list of the 19 gene clusters
identified can be found in Supplemental Data. Gene symbols and Entrez GeneIDs are shown on the right.
www.nature.com/scientificreports
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bipotent progenitor/stem cell). In any case, our observation that the
majority of Basal-like tumors are more similar to SQCLC than to the
rest of breast tumors, especially to the luminal tumors, suggests that
the cell of origin of Basal-like breast tumors has similar features and
location, in an epithelial layer, as the cell of origin of SQCLCs, which is
the basal cell present in the airway basal lamina32.
The transcriptomic similarities observed here between Basal-
like breast cancers and SQCLCs are also found at the DNA level.
Indeed, the most frequently mutated genes in Basal-like breast
tumors (i.e. TP53, PIK3CA and RB1) are also found in the top
10 significantly mutated genes in SQCLC. Of note, the most fre-
quently mutated gene in both tumors types is TP53 with a pre-
valence of ,80%. In addition, both cancer types also share many
focal regions of DNA amplification or deletion (Supplemental
Data). Among 28 significant focal DNA regions of amplification
in Basal-like breast cancer identified in the TCGA breast cancer
Figure 7 | Unsupervised hierarchical clustering of the 7 different cancer types and 329 gene signature scores. (A) 329 gene signatures and all tumor
samples. Each colored square on the heatmap represents the relative signature score (in log2 space) for each sample with highest expression
being red, lowest expression being green and average expression being black. On the right, selected signature groups were selected. Black bars to the right
identify the approximate locations of the selected groups. The signature scores of each sample can be found in Supplemental Data.
www.nature.com/scientificreports
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project10, 7 (25%) are also found in SQCLC: 8q24.21 (e.g. MYC),
8p11.23 (e.g. FGFR1), 7p11.2 (e.g. EGFR), 12p13.33 (e.g. FOXM1),
15q26.3 (e.g. ALDH1A3), 21q21.1 (e.g. miRNA-let-7c), 11q13.3
(e.g. FGF3 and FGF4). Among 36 significant focal DNA regions
of deletion in Basal-like breast cancer, 13 (36%) are also found in
SQCLC such as 10q23.31 (e.g. PTEN), 10q26.3 (e.g. INPP5A),
11q25 (e.g. ATM), 4p16.3 (e.g. INPP4B), 9p21.3 (e.g. CDKN2A
and CDKN2B) and 5q11.2 (e.g. RAD17). Finally, at the clinical
level, both cancer types have a poor prognosis with a high pro-
pensity for metastatic spread33–35. In terms of treatment response,
both show high sensitivity to platinum-based therapies36,37
although resistant disease easily emerges38.
Figure 8 | Expression of 6 selected gene signatures (SIGN) representing various cancer-related biological processes in the unified dataset. For each gene
signature, samples have been rank ordered based on their gene signature score (red, black and green represent above, equal and below the median score).
Samples from each cancer type are shown below the gene signature score heatmap. Percentages of samples present in the top 20% expressers in the
entire dataset are shown on the left. PROLIF, proliferation; EMT, epithelial to mesenchymal transition; TP53MUT, P53 mutation.
Table 1 | Breast cancer intrinsic subtyping of non-breast cancer types*
N Basal-like Claudin-low HER2-E Luminal A Luminal B Normal-like P-value*
CCR 220 1% 0% 99% 0% 0% 0% 0.172
CCR_CIN 88 0% 0% 100% 0% 0% 0%
CCR_Invasive 61 0% 0% 100% 0% 0% 0%
CCR_MSI/CIMP 71 3% 1% 96% 0% 0% 0%
GBM 202 0% 100% 0% 0% 0% 0% -
GBM_Classical 54 0% 100% 0% 0% 0% 0%
GBM_Mesenchymal 58 0% 100% 0% 0% 0% 0%
GBM_Neural 33 0% 100% 0% 0% 0% 0%
GBM_Proneural 57 0% 100% 0% 0% 0% 0%
OVARIAN 489 53% 8% 28% 0% 5% 6% ,0.001
OVARIAN_Differentiated 135 57% 0% 27% 0% 4% 13%
OVARIAN_Immunoreactive 107 48% 1% 40% 0% 11% 0%
OVARIAN_Mesenchymal 109 44% 26% 21% 1% 4% 5%
OVARIAN_Proliferative 138 62% 7% 24% 0% 2% 6%
SQCLC 122 55% 20% 24% 0% 0% 1% 0.004
SQCLC_Basal 32 78% 13% 9% 0% 0% 0%
SQCLC _Classical 45 47% 13% 40% 0% 0% 0%
SQCLC _Primitive 19 47% 26% 26% 0% 0% 0%
SQCLC _Secretory 26 46% 38% 12% 0% 0% 4%
LUAD 127 8% 16% 59% 9% 2% 6% ,0.001
LUAD_Magnoid 40 15% 5% 63% 8% 8% 3%
LUAD_Squamoid 43 9% 37% 53% 0% 0% 0%
LUAD_Bronchioid 44 0% 5% 61% 20% 0% 14%
Total 1707 26% 17% 30% 14% 9% 4% -
*, HER2-E, HER2-enriched. CCR, colorectal cancer; CIN, chromosomal instability; MSI/CIMP, microsatellite instability (MSI) located primarily in the right colon and frequently associated with the CpG
island methylator phenotype (CIMP); GBM, glioblastoma multiforme; SQCLC, squamous cell lung cancer; LUAD, lung adenocarcinoma. P-values have been obtained by performing a Chi-square test of the
subtype distribution within each cancer type.
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The TGCA breast cancer project has previously found common
genetic alterations between Basal-like breast cancer and high-grade
serous ovarian carcinomas10,11. Concordant with this, we observed
that most ovarian cancers show a Basal-like profile and are more
similar to Basal-like breast cancer than to the other cancer types
evaluated; conversely, Basal-like breast tumors are more similar to
both lung cancers and non-Basal-like breast cancer than to ovarian
cancer. The potential explanation for this non-reciprocity despite
that serous ovarian cancers and Basal-like breast tumors share many
alterations at the DNA level is currently unknown but might well be
related to the fact that the cell of origins of these two tumor types
might have different biological functions and/or epigenetic programs
in its respective organ. Although targeting a similar genetic alteration
in two different cancer types might be a successful strategy in some
cases (i.e. HER2 amplification in HER21 gastric and breast can-
cers)12,13, tumor cell context might also be important in other cases
as highlighted by the limited response observed so far to BRAF
inhibitors of BRAF (V600E) mutated colorectal cancers compared
to BRAF-mutated melanomas39.
Despite the differences in global gene expression profiles, ovarian
cancer does have a similar prevalence of TP53 mutations and RB1 as
Basal-like breast cancer and SQCLC. In addition, the three cancer
types also share 3 focal regions of DNA amplification (8q24.21,
12p13.33 and 15q26.3) and 10 focal regions of DNA deletion
(2q22.1, 2q37.3, 5q11.2, 9p21.3, 10q23.31, 10q26.3, 11q25, 16p13.3,
18q23 and 19p13.3) (Supplemental Data). Interestingly, our
expression analysis of DNA chromosomal regions and cytogenic
bands has also identified the 5q13-22 region as a commonly deleted
across the three cancer types. Interestingly, this DNA region contains
BRCA1-dependent DNA repair genes such as RAD17, RAD50 and
RAP80, and its deletion has been shown to increase sensitivity to a
PARP inhibitor and carboplatin in preclinical models of Basal-like
breast cancer40.
Over the years, the intrinsic subtypes of breast cancer (Luminal A,
Luminal B, HER2-enriched and Basal-like) have shown significant
differences in terms of survival, response to therapies and dissem-
ination patterns33. Identification of these ‘intrinsic’ profiles in non-
breast cancer types revealed interesting associations. For example,
virtually all CRCs in the TCGA and in two independent datasets were
identified as HER2-enriched despite ERBB2 not being overexpressed
or amplified8,41. This result suggests that another oncogene or driver
might be inducing a similar activation of the downstream signaling
pathways, including MAPK/RAS pathways, in a similar manner as
ERBB2. Interestingly, we have previously shown that the HER2-
enriched subtype can be identified in HER2-nonamplified breast
cancers (especially within the so-called triple-negative disease), and
these tumors tend to show high expression of EGFR42. Another
interesting observation has been the identification of the Luminal
A and B breast cancer ‘intrinsic’ profiles in 11% of lung adeno-
carcinomas, suggesting that these tumors are enriched for estrogen
receptor-regulated biological processes. Interestingly, substantial
preclinical evidence supports a role for hormonal influence on lung
cancer43,44, and treatment with estrogen plus progestin in women has
shown to increase deaths from lung cancer45.
Although we could identify common pattern of gene (or sig-
nature) expression across different cancer types, each cancer type
(including Basal-like breast cancer) is a unique molecular entity
when global gene expression analyses are performed. This prompted
us to identify a robust 126-gene signature (18 genes per cancer type)
that can identify the 6 cancer types. Interestingly, the list included
known cancer type specific biomarkers such WT-1 (for serous
ovarian cancer) and TITF-1 (for lung adenocarcinoma). Other bio-
markers somewhat related to specific cancer types were keratin 20
(KRT20) for CRCs, prolactin receptor (PRLR) for non-Basal-like
breast cancers, forkhead box C1 (FOXC1) for Basal-like breast can-
cers, tumor protein p63 (TP63, also known as TP73L) for SQCLCs,
various surfactant associated proteins (SFTPA2, SFTPC and SFTPD)
for LUADs and oligodendrocyte transcription factor 2 (OLIG2) for
GBMs.
To conclude, molecular screening for specific alterations in the
tumor cells and/or the tumor microenviroment such as DNA muta-
tions, DNA amplifications and RNA and protein expression, is
becoming commonplace inmany parts of theworld46. Patients whose
tumor has a specific biological alteration that might be inhibited by a
novel biological drug are being incorporated in early phase clinical
trials regardless of the cancer type. Indeed, a subset of gastric and
breast cancers showing amplification of HER2 benefit from anti-
HER2 therapies13,14. At the same time, various cancer types benefit
from anti-angiogenic (i.e. bevacizumab) and immune enhancers
(PD-L1 antibody)47,48. Although this strategy shows promise as evid-
ence by the results of some studies, it is still unknown how best to
approach it. Our data argues in favor of targeting commonmolecular
alterations of the tumor and/or the microenvironment regardless of
the tumor’s tissue of origin with a special focus on Basal-like breast
and squamous cell lung cancer.
Methods
Gene expression data from TCGA. All gene expression microarray data is publicly
available and can be obtained from the TCGA portal (https://tcga-data.nci.nih.gov/
tcga/).We evaluated a total of 1,580 samples from published cancer types fromTCGA
including glioblastoma multiforme5,6 (GBM, n 5 202), high-grade serous ovarian
carcinoma7 (named here ovarian cancer, n 5 489), breast cancer10 (n 5 547),
colorectal cancer8 (CCR, n5 220) and squamous cell lung carcinoma9 (SQCLC, n5
122). In addition, we also included 127 unpublished samples from the TCGA lung
adenocarcinoma (LUAD) project that are already publicly available in the TCGA
portal for a total of 1,707 samples. Of note, all microarrays were performed at the
University of North Carolina (UNC) under the same protocol and platform (Agilent
Technology, Santa Clara, CA). Briefly, 1 to 2 ug of total RNA sample and Stratagene
Universal Human Reference were amplified and labeled using Agilent’s Low RNA
Input Linear Amplification Kit. The total yield of amplified RNA (aRNA) and Cy dye
incorporation was measured by NanoDrop. Sample and reference 7–10 ug of each)
were co-hybridized to a Custom Agilent 244K Gene Expression Microarray. Arrays
were scanned on an Agilent Scanner and probe information was obtained with
Agilent’s Feature Extraction Software.
All microarray data was downloaded from the UNC UMD website (https://
genome.unc.edu/). The probes or genes for all analyses were filtered by requiring the
lowess normalized intensity values in both sample and control to be .10. The nor-
malized log2 ratios (Cy5 sample/Cy3 control) of probes mapping to the same gene
(Entrez ID as defined by the manufacturer) were averaged to generate independent
expression estimates of a total of 17,987 genes. No significant batch effects based on
the microarray chip barcode were observed (Suppl. Fig. 8–9).
Gene expression signatures. In the unified dataset, we evaluated 329 gene signatures
using the gene lists and algorithms previously described20,21,23,49–51. In addition, we
evaluated the percentage of tumors within a cancer type that falls within the top-20%
expressers in the unified dataset for the following gene sigantures: a TP53 mutation
signature21, a VEGF13-hypoxia signature49, an immune cell signature19, a 11-gene
proliferation signature23, a PTEN loss signature50 and an epithelial-to-mesenchymal
transition (EMT) signature51.
To identify the breast cancer ‘intrinsic’ subtype in non-breast tumors (Luminal A,
Luminal B, HER2-enriched, Basal-like, Claudin-low and Normal-like), we used the
PAM50 intrinsic subtype classifier23 and the Claudin-low subtype predictor22 after
gene centering the combined dataset onto the breast cancer dataset. To ensure sub-
typing of non-breast cancers was correctly implemented, we compared the subtype
calls obtained in breast cancers compared to the subtype calls provided in the TCGA
breast cancer datasets.
Subtype identification. For all cancer types, except LUAD, we used the subtype calls
as provided in each TCGA publication5–9. For LUADs, we used the tumor centroids
provided in Wilkerson et al.52 and assigned a subtype call (Bronchioid, magnoid and
squamoid) for each LUAD using Single Sample Predictor (SSP).
Immunohistochemical (IHC) analyses.We selected 3 tumors representing a Basal-
like breast cancer, a SQCLC with a PAM50 Basal-like profile and a Luminal A breast
cancer. To confirm the intrinsic subtype of the two breast tumors and the Basal-like
profile of the lung cancer, we performed expression analyses of the 50 PAM50 genes
(and 5 house-keeping genes) using the nCounter Nanostring platform after purifying
,100 ng of total RNA from the same tumor block where IHC analyses were
performed. Immunohistochemical staining using the avidin-biotin-peroxidase
technique was performed for each antibody. Five-micrometer-thick sections were cut
from the tissue specimens and placed on poly-L-lysine–coated glass slides. Sections
were deparaffined by xylene and rehydrated in graded alcohol. Endogenous
peroxidase was blocked by immersing the sections in 0.1% hydrogen peroxidase in
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absolute methanol for 20 min. For antigen retrieval, the tissue sections were heated in
a pressure cooker in citric acid monohydrate 10 mM, pH 6.0, for 5 min, and then
incubated with the primary antibody at room temperature. IHC was performed with
Benchmark XT (VentanaMedical Systems, Inc, Tucson, AZ). The primary antibodies
and dilutions used were: anti-ER (Ventana Medical Systems, prediluted), anti-Ki-67
(Ventana Medical Systems, prediluted), anti-CK5/6 (Biocare, prediluted). All slides
were hematoxylin counterstained, dehydrated, and mounted. Omitting the primary
antibody performed negative controls.
Evaluation of two independent gene expression-based datasets. The first dataset is
a publicly available microarray dataset (GSE23768, Affymetrix Human Exon 1.0 ST
Array)24 that includes 153 samples of breast cancer (n5 84), CCR (n5 26), SQCLC
(n5 22) and LUAD (n5 21). Normalized data was obtained from Gene Expression
Omnibus, and only themost variable probes (i.e. highest inter-quartile range) for each
gene were considered for further analyses.
The second dataset is an in-house dataset of VHIO that includes 53 formalin-fixed
paraffin-embedded (FFPE) breast samples representing all the subtypes and 72
primary untreated FFPE CCRs. We performed expression analyses of 49 of the 50
PAM50 genes (and 5 house-keeping genes) using the nCounter Nanostring platform
after purifying ,100 ng of total RNA.
Statistical analysis. From the combined microarray dataset, we selected the most
variable genes within each cancer-type (breast, ovarian, LUAD, SQCLC, GBM and
CCR) by selecting 3,486 genes with an interquartile range (i.e. difference between the
upper and lower quartiles), which is a measure of statistical dispersion, of at least 3-
fold (Supplemental Data). To estimate the ‘distance’ of each sample to each cancer
type centroid, we calculated the Euclidean distance using SSP. Differences between
‘distances’ of each sample to two centroids were used to determine the grade of
similarity.
All microarray cluster analyses were displayed using Java Treeview version 1.1.4r2
and can be found in supplemental materials. Average-linkage hierarchical clustering
was performed using Cluster v3.053. Biologic analysis of microarray data was per-
formed with DAVID annotation tool (http://david.abcc.ncifcrf.gov/)54. Only signifi-
cant (p , 0.001) Gene Ontology enrichments are shown in the text. Consensus
clustering plus (http://bioc.ism.ac.jp/2.6/bioc/html/ConsensusClusterPlus.html)16
and principal complement plots of gene expression data were performed using R
(http://cran.r-project.org).
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